ArticleScientific reports2025
Exploring Pharmacokinetic interactions between SHR8554, a µ-opioid receptor biased agonist, and Itraconazole in healthy Chinese subjects.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07277153 (Clinical Study on the Effect of Tegileridine on Postoperative Pain in PatientsUndergoing Abdominal Surgery：A Randomized Controlled Double-blind Trial.), which is not on this map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Study on the Effect of Tegileridine on Postoperative Pain in PatientsUndergoing Abdominal Surgery：A Randomized Controlled Double-blind Trial.
Who cites it
3 citing papers in PubMed.
- Safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR8554, a biased µ-opioid receptor agonist: a phase I trial in healthy volunteers.BMC pharmacology & toxicology · 2026Trial
- A Comparison of Tegileridine Fumarate versus Sufentanil on the Quality of Postoperative Recovery After Laparoscopic Sleeve Gastrectomy: A Preliminary Randomized Controlled Trial.Drug design, development and therapy · 2026Trial
- Establishing the Median Effective Dose of Tegileridine for Immediate Postoperative Analgesia Following Laparoscopic Colorectal Cancer Surgery: A Sequential Dose-Finding Study.Drug design, development and therapy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SHR8554 is a biased agonist for µ-opioid receptors, which was under investigation as an alternative therapy for clinical pain. This open, fixed-sequence study evaluated its pharmacokinetic (PK) interaction with itraconazole, a strong CYP3A4 inhibitor. Subjects (n = 16) were given SHR8554 (1 mg) intravenously on Day 1 and Day 9, and itraconazole capsules (200 mg) twice a day orally from Day 4 to Day 10. Liquid chromatography tandem mass spectrometry was applied for plasma concentration of SHR8554. After single dose of SHR8554, the C
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.